insights_auto
Why is ABVX down 17,21%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
63,00 €
arrow_downward
-17,21%(-13,10) 1D
20 ნოე, 17:38:58 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
74,50 €
High
74,50 €
Low
59,30 €
Mkt. cap
5,57 მლრდ.
Avg. vol.
112,96 ათ.
Volume
842,42 ათ.
52-wk high
139,00 €
52-wk low
59,30 €
EPS
-5,20 €
Shares outstanding
87,55 მლნ.
No. of employees
98
Open
74,50 €
High
74,50 €
Low
59,30 €
Mkt. cap
5,57 მლრდ.
Avg. vol.
112,96 ათ.
Volume
842,42 ათ.
52-wk high
139,00 €
52-wk low
59,30 €
EPS
-5,20 €
Shares outstanding
87,55 მლნ.
No. of employees
98
News stories
From web sources and news partners
TradingView
·
2 საათის წინ
Stock Market Crash: Nasdaq, S&P 500 Suffer Worst Weekly Losses in Years
Traders Union
·
7 საათის წინ
VIX fear index hits highest level since April 2025 as S&P 500 plunges
Beinsure
·
4 საათის წინ
S&P 500 forecast for 2027: Wall Street expects a rebound after an 11.6% drop fueled by AI fears
JournalArta
·
15 წუთის წინ
S&P 500 Loses Nearly All Its 2026 Gains in Sudden Reversal
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOმარკ დე გარიდელი | ჰარტმუტ ჯეი ერლიხი
Employees98
Founded4 დეკ. 2013
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteabivax.com